Compass Therapeutics, Inc. (CMPX)
Data as of , from SEC Form 4 filings.
See up to 3 months of CMPX. The 7-day demo opens the 1M and 3M ranges and puts CMPX on your watchlist.
Start 7-day demoData as of , from SEC Form 4 filings.
See up to 3 months of CMPX. The 7-day demo opens the 1M and 3M ranges and puts CMPX on your watchlist.
Start 7-day demo
Jonathan Anderman - Officer
Thomas J. Schuetz - OfficerThomas J. Schuetz - OfficerCompass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
https://www.compasstherapeutics.comSEC filings for CMPX on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 22,500 | $21K |
22 Form 4 filings on record, the earliest from Dec 10, 2024, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Neil Lerner - Officer | Open-market purchase | Common Stock | 20,000 | $0.92 | $18K | |
| Neil Lerner - Officer | Open-market purchase | Common Stock | 2,500 | $1.14 | $3K | |
| Jonathan Anderman - Officer | Grant or award | Common Stock | 25,000 | $1.89 | $47K | |
| Neil Lerner - Officer | Grant or award | Common Stock | 15,000 | $1.89 | $28K | |
| Thomas J. Schuetz - Officer | Tax withholding / forfeiture | Common Stock | 36,687 | $6.52 | $239K | |
| Thomas J. Schuetz - Officer | Tax withholding / forfeiture | Common Stock | 46,777 | $5.35 | $250K | |
| Barry Shin - Officer | Grant or award | Common Stock | 125,000 | $5.17 | $646K | |
| Barry Shin - Officer | Grant or award | Stock Option (Right to Buy) | 670,000 | $0.00 | - | |
| Cynthia Sirard - Officer | Grant or award | STOCK OPTION (RIGHT TO BUY) | 1,000,000 | $0.00 | - | |
| Thomas J. Schuetz - Officer | Grant or award | Common Stock | 250,000 | $5.17 | $1.29M | |
| Thomas J. Schuetz - Officer | Grant or award | Stock Option (Right to Buy) | 2,000,000 | $0.00 | - | |
 Arjun Prasad - Officer | Grant or award | STOCK OPTION (RIGHT TO BUY) | 1,000,000 | $0.00 | - | |
| Richard S. Lindahl - Director | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
 Ellen Chiniara - Director | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
| Neil Lerner - Officer | Grant or award | Common Stock | 62,500 | $5.17 | $323K | |
| Neil Lerner - Officer | Grant or award | Stock Option (Right to Buy) | 435,000 | $0.00 | - | |
| Mary Ann Gray - Director | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
| James P. Boylan - Director | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
| Carl L. Gordon - Director | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
| Philip Ferneau - Director | Grant or award | Stock Option (Right to Buy) | 90,000 | $0.00 | - | |
| Jonathan Anderman - Officer | Grant or award | Common Stock | 150,000 | $5.17 | $776K | |
| Jonathan Anderman - Officer | Grant or award | Stock Option (Right to Buy) | 720,000 | $0.00 | - | |
| Thomas J. Schuetz - Officer | Tax withholding / forfeiture | Common Stock | 44,025 | $4.83 | $213K | |
| Carl L. Gordon - Director | Open-market sale | Common Stock | 3,571,428 | $1.59 | $5.68M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 3,571,428 | $1.59 | $5.68M | |
| Barry Shin - Officer | Grant or award | Common Stock | 400,000 | $1.65 | $660K | |
| Barry Shin - Officer | Grant or award | Stock Option (Right to Buy) | 400,000 | $0.00 | - |
Compass Therapeutics, Inc. (CMPX) had 2 insider filings in the last 90 days, with the most recent on 2 October 2026. The full record for CMPX runs to 22 Form 4 filings, the earliest from 10 December 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
2 insider purchases of CMPX were filed in the last 90 days, totaling $21K.
No insider sales of CMPX were filed in the last 90 days. 2 sales are on record for this company.
This page collects CMPX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
